Bone Void Fillers Market Growing at 6%

Stable but promising.

Such is the prognosis for the global bone void fillers market, whose value is estimated at $3.5 billion (2022), and is growing 6% annually, according to Medi-Tech Insights. The market’s expansion is driven by the prevalence of orthopedic disorders and technological advancements. As the global population ages, the number of people suffering from orthopedic disorders is growing. In the United States, about 1.5 million people are diagnosed with osteoporosis each year. Moreover, the International Osteoporosis Foundation predicts the number of osteoporotic fractures in Europe (EU27, Switzerland and the U.K.) will grow roughly 25% to reach 5.3 million in 2034 from 4.3 million in 2019. 

A bone void is a cavity in bone that results from a failure of the bone’s self-healing process. Healthy bone tissue can be lost or damaged as a result of infection, trauma, tumours or orthopedic procedures. A bone void filler/graft is a material used to fill a bone defect or a void to correct these conditions. Bony voids can be filled using autografts, allografts, and synthetic grafts.
 
Infection is major problem after orthopedic procedures and may lead to serious consequences. Owing to this, key players are focusing on launching bone void fillers formulated in combination with antibiotics. In June 2021, Elute Inc. received U.S. Food and Drug Administration (FDA) authorization to use its EP Granules with Tobramycin in a clinical trial. The product is a resorbable bone void filler that delivers a broad-spectrum antibiotic in a local and targeted manner in the surgical treatment of bone infections following hip or knee replacements. Further, BONESUPPORT (a Scandinavian company) has gained FDA approval for its antibiotic bone void filler product called CERAMENT G. A DeNovo application for CERAMENT G for bone infections was submitted in April 2020 and is expected to gain approval this year.
 
From a geographic perspective, North America has a major market share of global bone void fillers revenues. This is mainly attributed to the large number of orthopedic procedures, growing aging population, and relatively higher penetration of bone void filling products in the region.
 
As a key growth strategy, companies operating in the bone void fillers market are focusing on launching new and advanced products to gain market share. For instance, in February 2022, Orthofix Medical launched a synthetic bioactive bone graft (Opus BA) for spine procedures and In January 2022, Bone Solutions Inc. (BSI) launched Mg OSTEOINJECT, an injectable Magnesium-based bone void filler. In September 2021, Orthofix Medical launched the Opus Mg Set osteoconductive scaffold, a synthetic magnesium-based bone void filler for orthopedic procedures. Opus Mg Set provides a procedure-specific solution for orthopedic fracture and trauma procedures by filling non-structural bony voids or gaps during surgery.

Some key players operating in the global bone void filler market are Medtronic, Graftys, DePuy Synthes Companies (JnJ), Stryker Corp., Baxter, Bioventus, Orthofix, Bone Solutions Inc., Curasan Inc., Olympus Terumo Biomaterials Corporation, Biocomposites, Arthrex, Zimmer Biomet Holdings Inc., Collagen Matrix, and Bonesupport AB, among others.